{
    "root": "317b1f6d-746c-42a1-ba4a-9c6e18fda2b8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Imatinib Mesylate",
    "value": "20250326",
    "ingredients": [
        {
            "name": "IMATINIB MESYLATE",
            "code": "8A1O1M485B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_45783"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        }
    ],
    "indications": {
        "text": "imatinib mesylate kinase inhibitor indicated treatment : \u2022 newly diagnosed adult pediatric patients philadelphia chromosome positive chronic myeloid leukemia ( ph+ cml ) chronic phase ( 1.1 ) \u2022 patients philadelphia chromosome positive chronic myeloid leukemia ( ph+ cml ) blast crisis ( bc ) , accelerated phase ( ap ) , chronic phase ( cp ) failure interferon-alpha therapy ( 1.2 ) \u2022 adult patients relapsed refractory philadelphia chromosome positive acute lymphoblastic leukemia ( ph+ ) ( 1.3 ) \u2022 pediatric patients newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ( ph+ ) combination chemotherapy ( 1.4 ) \u2022 adult patients myelodysplastic/myeloproliferative diseases ( mds/mpd ) associated platelet-derived growth factor receptor ( pdgfr ) gene re-arrangements . ( 1.5 ) \u2022 adult patients aggressive systemic mastocytosis ( asm ) without d816v c-kit mutation c-kit mutational status unknown ( 1.6 ) \u2022 adult patients hypereosinophilic syndrome ( hes ) and/or chronic eosinophilic leukemia ( cel ) fip1l1-pdgfr\u03b1 fusion kinase ( mutational analysis fluorescence situ hybridization [ fish ] demonstration chic2 allele deletion ) patients hes and/or cel fip1l1-pdgfr\u03b1 fusion kinase negative unknown . ( 1.7 ) \u2022 adult patients unresectable , recurrent and/or metastatic dermatofibrosarcoma protuberans ( dfsp ) ( 1.8 ) \u2022 patients kit ( cd117 ) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors ( gist ) . ( 1.9 ) \u2022 adjuvant treatment adult patients following resection kit ( cd117 ) positive gist . ( 1.10 )",
        "doid_entities": [
            {
                "text": "chronic myeloid leukemia (DOID:8552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8552"
            },
            {
                "text": "myeloid leukemia (DOID:8692)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8692"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            },
            {
                "text": "cml (DOID:1036)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1036"
            },
            {
                "text": "acute lymphoblastic leukemia (DOID:9952)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9952"
            },
            {
                "text": "lymphoblastic leukemia (DOID:1037)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1037"
            },
            {
                "text": "aggressive systemic mastocytosis (DOID:4798)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4798"
            },
            {
                "text": "systemic mastocytosis (DOID:349)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_349"
            },
            {
                "text": "mastocytosis (DOID:350)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_350"
            },
            {
                "text": "hypereosinophilic syndrome (DOID:999)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_999"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "chronic eosinophilic leukemia (DOID:0080367)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080367"
            },
            {
                "text": "dermatofibrosarcoma protuberans (DOID:3507)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3507"
            },
            {
                "text": "stromal tumors (DOID:2991)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2991"
            },
            {
                "text": "gist (DOID:9253)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9253"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic myeloid leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_521"
            },
            {
                "disease": "chronic eosinophilic leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_168940"
            },
            {
                "disease": "acute lymphoblastic leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_513"
            }
        ]
    },
    "contraindications": {
        "text": "adults ph+ cml cp ( 2.2 ) : 400 mg/day adults ph+ cml ap bc ( 2.2 ) : 600 mg/day pediatrics ph+ cml cp ( 2.3 ) : 340 mg/m 2 /day adults ph+ ( 2.4 ) : 600 mg/day pediatrics ph+ ( 2.5 ) 340 mg/m 2 /day adults mds/mpd ( 2.6 ) : 400 mg/day adults asm ( 2.7 ) : 100 mg/day 400 mg/day adults hes/cel ( 2.8 ) : 100 mg/day 400 mg/day adults dfsp ( 2.9 ) : 800 mg/day adults metastatic and/or unresectable gist ( 2.10 ) : 400 mg/day adjuvant treatment adults gist ( 2.11 ) : 400 mg/day patients mild moderate hepatic impairment ( 2.12 ) : 400 mg/day patients severe hepatic impairment ( 2.12 ) : 300 mg/day doses imatinib mesylate tablets taken meal large glass water . doses 400 mg 600 mg ( imatinib free base ) administered daily , whereas dose 800 mg ( imatinib free base ) administered 400 mg ( imatinib free base ) twice day . imatinib mesylate tablets dissolved water apple juice patients difficulty swallowing . daily dosing 800 mg ( imatinib free base ) accomplished using 400 mg tablet ( imatinib free base ) reduce exposure iron .",
        "doid_entities": [
            {
                "text": "cml (DOID:1036)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1036"
            },
            {
                "text": "asm (DOID:4798)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4798"
            },
            {
                "text": "gist (DOID:9253)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9253"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "imatinib mesylate film-coated tablet contains 100 mg 400 mg imatinib free base . \u2022100 mg tablets brownish orange , slightly biconvex , round film-coated tablets functional scoring , engraved `` ima `` score `` 100 `` one side , `` apo `` side cartons 30 ( 10 tablets per blister pack x 3 ) ndc 0904-6901-04 \u2022400 mg tablets brownish orange , capsule shaped , biconvex film-coated tablets functional scoring , engraved `` ima `` score `` 400 `` one side , `` apo `` side cartons 30 ( 10 tablets per blister pack x 3 ) ndc 0904-6621-04 storage handling store 20\u00bac 25\u00bac ( 68\u00baf 77\u00baf ) ; excursions permitted 15\u00b0c 30\u00bac ( 59\u00b0f 86\u00baf ) [ usp controlled room temperature ] . protect moisture . dispense tight container , usp . crush imatinib mesylate tablets . avoid direct contact crushed tablets skin mucous membranes . contact occurs , wash thoroughly outlined references . avoid exposure crushed tablets .",
    "adverseReactions": "none .",
    "indications_original": "Imatinib mesylate is a kinase inhibitor indicated for the treatment of: \u2022 Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) \u2022 Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) \u2022 Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) \u2022 Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy ( 1.4 ) \u2022 Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) \u2022 Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown ( 1.6 ) \u2022 Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR\u03b1 fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR\u03b1 fusion kinase negative or unknown. ( 1.7 ) \u2022 Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) \u2022 Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) \u2022 Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 )",
    "contraindications_original": "Adults with Ph+ CML CP ( 2.2 ): 400 mg/day Adults with Ph+ CML AP or BC ( 2.2 ): 600 mg/day Pediatrics with Ph+ CML CP ( 2.3 ): 340 mg/m 2 /day Adults with Ph+ ALL ( 2.4 ): 600 mg/day Pediatrics with Ph+ ALL ( 2.5 ) 340 mg/m 2 /day Adults with MDS/MPD ( 2.6 ): 400 mg/day Adults with ASM ( 2.7 ): 100 mg/day or 400 mg/day Adults with HES/CEL ( 2.8 ): 100 mg/day or 400 mg/day Adults with DFSP ( 2.9 ): 800 mg/day Adults with metastatic and/or unresectable\u00a0GIST\u00a0( 2.10 ): 400 mg/day Adjuvant treatment of adults with\u00a0GIST\u00a0( 2.11 ): 400 mg/day Patients with mild to moderate hepatic impairment ( 2.12 ): 400 mg/day Patients with severe hepatic impairment ( 2.12 ): 300 mg/day All doses of imatinib mesylate tablets should be taken with a meal and a large glass of water. Doses of 400 mg or 600 mg (imatinib as free base) should be administered once daily, whereas a dose of 800 mg (imatinib as free base) should be administered as 400 mg (imatinib as free base) twice a day. Imatinib mesylate tablets can be dissolved in water or apple juice for patients having difficulty swallowing. Daily dosing of 800 mg (imatinib as free base) and above should be accomplished using the 400 mg tablet (imatinib as free base) to reduce exposure to iron.",
    "warningsAndPrecautions_original": "Each imatinib mesylate film-coated tablet contains 100 mg or 400 mg of imatinib free base. \n                  \n                     \n                        \u2022100 mg Tablets\n                  \n                  Brownish orange, slightly biconvex, round film-coated tablets with functional scoring, engraved \"IMA\" over score \"100\" on one side, \"APO\" on the other side\n                  Cartons of 30 (10 tablets per blister pack x 3) NDC 0904-6901-04\n                  \n                     \n                        \u2022400 mg Tablets \n                  \n                  Brownish orange, capsule shaped, biconvex film-coated tablets with functional scoring, engraved \"IMA\" score \"400\" on one side, \"APO\" on the other side\n                  Cartons of 30 (10 tablets per blister pack x 3) NDC 0904-6621-04\n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF); excursions permitted from 15\u00b0C to 30\u00baC (59\u00b0F to 86\u00baF) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Dispense in a tight container, USP.\n                  Do not crush imatinib mesylate tablets. Avoid direct contact of crushed tablets with the skin or mucous membranes. If such contact occurs, wash thoroughly as outlined in the references. Avoid exposure to crushed tablets.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Imatinib Mesylate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_45783"
        }
    ]
}